Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability of a trend and profit from it.
Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors — such as sound fundamentals, positive earnings estimate revisions, etc. — that could keep the momentum in the stock going.
Investors looking to make a profit from stocks that are currently on the move may find our "Recent Price Strength" screen pretty useful. This predefined screen comes handy in spotting stocks that are on an uptrend backed by strength in their fundamentals, and trading in the upper portion of their 52-week high-low range, which is usually an indicator of bullishness.
There are several stocks that passed through the screen and Catalyst Pharmaceutical (CPRX) is one of them. Here are the key reasons why this stock is a solid choice for "trend" investing.
A solid price increase over a period of 12 weeks reflects investors' continued willingness to pay more for the potential upside in a stock. CPRX is quite a good fit in this regard, gaining 13.2% over this period.
However, it's not enough to look at the price change for around three months, as it doesn't reflect any trend reversal that might have happened in a shorter time frame. It's important for a potential winner to maintain the price trend. A price increase of 27.1% over the past four weeks ensures that the trend is still in place for the stock of this specialty drug company.
Moreover, CPRX is currently trading at 93% of its 52-week High-Low Range, hinting that it can be on the verge of a breakout.
Looking at the fundamentals, the stock currently carries a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises — the key factors that impact a stock's near-term price movements.
The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Another factor that confirms the company's fundamental strength is its Average Broker Recommendation of #1 (Strong Buy). This indicates that the brokerage community is highly optimistic about the stock's near-term price performance.
So, the price trend in CPRX may not reverse anytime soon.
In addition to CPRX, there are several other stocks that currently pass through our "Recent Price Strength" screen. You may consider investing in them and start looking for the newest stocks that fit these criteria.
This is not the only screen that could help you find your next winning stock pick. Based on your personal investing style, you may choose from over 45 Zacks Premium Screens that are strategically created to beat the market.
However, keep in mind that the key to a successful stock-picking strategy is to ensure that it produced profitable results in the past. You could easily do that with the help of the Zacks Research Wizard. In addition to allowing you to backtest the effectiveness of your strategy, the program comes loaded with some of our most successful stock-picking strategies.
Click here to sign up for a free trial to the Research Wizard today.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Catalyst Pharmaceuticals, Inc. (CPRX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Persistent supply chain disruptions and inflation pressures are constraining the global economy's recovery from the COVID-19 pandemic, the International Monetary Fund said on Tuesday as it cut growth outlooks for the United States and other major industrial powers. In its World Economic Outlook, the IMF trimmed its 2021 global growth forecast to 5.9% from the 6.0% forecast it made in July.
First Mining Gold Corp. ("First Mining" or the "Company") (TSX: FF) (OTCQX: FFMGF) (FRANKFURT: FMG) is pleased to announce the appointment of James Maxwell as Vice President, Exploration effective October 25, 2021.
'The Big Short' guy remains bearish. But he's long on this trio of stocks.
In this article, we discuss the 11 best Robinhood stocks to buy according to hedge funds. If you want to skip our detailed analysis of these stocks, go directly to the 5 Best Robinhood Stocks To Buy According To Hedge Funds. Equity trading applications have become more famous as the rapid digitization of the world […]
Worried about inflation? You should be — especially if you own the wrong assets and bet against S&P 500 and growth stocks.
In this article, we discuss the Ark Invest Stock Portfolio: Top 10 Picks. If you want to skip our detailed analysis of these ARK stocks, go directly to the Ark Invest Stock Portfolio: Top 5 Picks. Cathie Wood, a well-known disruptive innovation investor, established ARK Investment Management in 2014 intending to create high-growth stock portfolios […]
No one can accuse Elon Musk of lacking in ambition and often throughout his career, Tesla’s (TSLA) detractors have had to beat a hasty retreat after underestimating the guru-like CEO’s ability to defy the skeptics. However, following the EV leader’s 2021 Annual Meeting, Needham’s Rajvindra Gill thinks the company’s ambitious goal does not seem realistic. The company reiterated its intention to deliver 20 million EVs by 2030 while at the same time making their offerings more affordable. “Although
Yahoo Finance’s Jared Blikre reports on the day's trending tickers.
Nio Inc – ADR (NYSE: NIO) shares have lagged the S&P 500 in 2021, generating a year-to-date total return loss of 27.1%. Nio’s stock has run out of steam in 2021, but value investors may be wondering whether it’s time to buy the dip. Earnings: A price-to-earnings ratio (PE) is one of the most basic fundamental metrics for gauging a stock’s value. The lower the PE, the higher the value. For comparison, the S&P 500’s PE is currently at about 34, more than double its long-term average of 15.9. Nio d
Shares of Chinese real estate firms fell further on Thursday as investors fretted about a debt crisis rippling through developers including China Evergrande Group, a day after the sector was hit with fresh rating downgrades. Evergrande, which has more than $300 billion in liabilities and 1,300 real estate projects in over 280 cities, missed a third round of interest payments on its international bonds this week, spooking investors. The world's most indebted developer, which has been trying to sell assets to raise funds, appeared to have made small progress towards that goal when Qumei Home Furnishings Group announced in a filing on Thursday that it will buy out Evergrande group's 40% stake in their furnishings joint venture for 72 million yuan ($11.18 million).
Toymaker Hasbro Inc said on Tuesday longtime Chairman and Chief Executive Officer Brian Goldner has died, two days after he went on medical leave. In a statement last year, Goldner said he had been under continued medical treatment following his cancer diagnosis in 2014. Board member and former CEO of marketing firm InnerWorkings Inc, Rich Stoddart, has replaced Goldner on an interim basis.
Since 2014, Harvard-educated David Yermack, a professor of finance at New York University, has taught courses on cryptocurrency. “Crypto investors should be aware of the high volatility of these assets, the unregulated nature of the trading platforms and the numerous frictions and delays involved in executing trades,” says Yermack.
Based on analysts' loftiest price targets, these companies could nearly triple or potentially quintuple investors' money over the next year.
Decrypt Editor-in-Chief Dan Roberts breaks down what crypto investors need to know about Shiba Inu.
For investors seeking the best returns, the decision of where to put the initial investment typically comes down to two choices. Put all the eggs in one big basket, and buy into the market’s giant corporations, the trillion-dollar companies with famously high share prices and a track record of steady growth – or to buy low, find a group of low-cost stocks in companies with sound business footings and high potential upside. It all comes down to just how much of a return do you want. The market's
What happened Shares of InMode (NASDAQ: INMD) leaped 8.6% on Tuesday after the medical technology specialist boosted its full-year financial forecast. So what InMode anticipates third-quarter revenue of $93.
Yahoo Finance's Brian Sozzi, Julie Hyman, and Brian Cheung break down the third quarter earnings results from JPMorgan.
Dow Jones futures rose modestly Wednesday night, along with S&P 500 futures and Nasdaq futures. The stock market rally attempt had a decent session on the major indexes, closing near highs as the 10-year Treasury yield retreated. AMD stock, CrowdStrike, Bill.com and Sea Limited moved above buy points.
Yahoo Finance's Brian Sozzi and Julie Hyman break down how Blackrock, Apple, and Qualcomm are faring in Wednesday's market.
Shares of Chinese electric vehicle maker Nio (NYSE: NIO) have had positive momentum for more than a week now, and that has continued today. As of 11 a.m. EDT, Nio shares had gained 3%. Last week, Chinese electric vehicle and battery maker BYD, which is one of Warren Buffett's Berkshire Hathaway portfolio holdings, announced plans to collaborate with a fleet-as-a-service solutions joint venture to deploy up to 5,000 new EVs to fleet managers in the U.S. And yesterday, news came that global EV leader Tesla had produced a record volume of electric vehicles at its Shanghai factory in September, with the majority of those sales remaining in China.